VEGFA and hereditary clear cell renal cell carcinoma: The simultaneous blockade of both VEGF-A and VEGFRs, using Bev and multi-kinase inhibitors, was reported to be more clinically efficacious for patients with advanced solid cancers, including melanoma, and renal cell carcinoma [25,26,27,28,29].